Journal of Computer-Aided Molecular Design

, Volume 19, Issue 5, pp 287–291 | Cite as

Asp746 to Glycine Change May have a Greater Influence than Cys751 to Serine Change in Accounting for Ligand Selectivity between EGFR and HER-2 at the ATP Site

  • Shantaram A. Kamath
  • John K. Buolamwini


We have carried out up to 8.0 ns molecular dynamics simulation on the ATP-bound complexes of EGFR and HER-2 (homology model) receptor kinase domains to explore the possible consequences of amino acid residue changes in or close to the ATP site that might provide insights for selectivity of these kinases towards ATP site inhibitors. The simulation results show the formation of a channel under Thr766 following the movement of the side chain of Gln767 away from the hinge in EGFR. In HER-2, a similar movement of Gln799 occurs, but a simultaneous movement of Arg784 towards the hinge region occurs that tends to close the channel. The movement of Arg784 in HER-2 appears to result from the absence of an anchoring residue like Asp746 in EGFR, which has been changed to Gly778 in HER-2. In EGFR, this Arg784 is held away from the hinge region by interaction with Asp746, thereby leaving the channel open. This might be an important contributory factor to differences in selectivity of the ligands between the two kinases, probably more so than the conservative change of Cys751 of EGFR to serine in HER-2 at the ATP site.

Key words

EGFR HER-2 kinase molecular dynamics selectivity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fantl, W.J., Johnson, D.E., Williams, L.T. 1993Ann. Rev. Biochem.62453PubMedGoogle Scholar
  2. 2.
    Ullrich, A., Schlessinger, J. 1991Cell61203CrossRefGoogle Scholar
  3. 3.
    Kolibaba, K.S., Druker, B.J. 1997Biochim. Biophys. Acta1333F217PubMedGoogle Scholar
  4. 4.
    Aaronson, S.A. 1991Science2541146PubMedGoogle Scholar
  5. 5.
    Menard, S., Pupa, S.M., Campiglio, M., Tagliabue, E. 2003Oncogene226570CrossRefPubMedGoogle Scholar
  6. 6.
    Bridges, A.J. 2001Chem. Rev.1012541CrossRefPubMedGoogle Scholar
  7. 7.
    Stamos, J., Sliwkowski, M.X., Eigenbrot, C. 2002J. Biol. Chem.27746,265Google Scholar
  8. 8.
    Kamath, S., Buolamwini, J.K. 2003J. Med. Chem.464657CrossRefPubMedGoogle Scholar
  9. 9.
    Blencke, S., Ullrich, A., Daub, H.J. 2003Biol. Chem.27815,435Google Scholar
  10. 10.
    Jones, G., Willet, P., Glen, R.C., Leach, A.R., Taylor, R. 1997J. Mol. Biol.267727CrossRefPubMedGoogle Scholar
  11. 11.
    Kale, L., Skeel, R., Bhandarkar, M., Brunner, R., Gursoy, A., Krawetz, N., Phillips, J., Shinozaki, A., Varadarajan, K., Schulten, K. 1999J. Comp. Phys.151283CrossRefGoogle Scholar
  12. 12.
    Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., Karplus, M. 1983J. Comp. Chem.4187CrossRefGoogle Scholar
  13. 13.
    MacKerell, A.D.,Jr., Bashford, D., Bellott, M., Dunbrack, R.L.,Jr., Evanseck, J.D., Field, M.J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F.T.K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D.T., Prodhom, B., Reiher, W.E.,III, Roux, B., Schlenkrich, M., Smith, J.C., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-Kuczera, J., Yin, D., Karplus, M. 1998J. Phys. Chem. B1023586CrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations